Results of a Survey on Diagnostic Procedures and Treatment Choices for Neuromyelitis Optica Spectrum Disorder in Korea: Beyond the Context of Current Clinical Guidelines
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Neuromyelitis optica spectrum disorder (NMOSD) is a rare demyelinating disease of the central nervous system (CNS). We investigated the medical behaviors of experts in Korea when they are diagnosing and treating NMOSD. Methods An anonymous questionnaire on the diagnosis and treatment of NMOSD was distributed to experts in CNS demyelinating diseases. Results Most respondents used the 2015 diagnostic criteria for NMOSD and applied a cerebrospinal fluid examination, magnetic resonance imaging (MRI) of the brain and spine, and anti-aquaporin-4 antibody testing to all suspected cases of NMOSD. All respondents prescribed steroid pulse therapy as an first-line therapy in the acute phase of NMOSD, and 67% prescribed azathioprine for maintenance therapy in NMOSD. However, details regarding monitoring, the tapering period of oral steroids, second-line therapy use in refractory cases, management during pregnancy, and schedule of follow-up MRI differed according to the circumstances of individual patients. We analyzed the differences in response rates between two groups of respondents according to the annual number of NMOSD patients that they treated. The group that had been treating ≥10 NMOSD patients annually preferred rituximab more often as the second-line therapy (p=0.011) and had more experience with rituximab treatment (p=0.015) compared with the group that had been treating <10 NMOSD patients. Conclusions This study has revealed that NMOSD experts in Korea principally follow the available treatment guidelines. However, the differences in specific clinical practices applied to uncertain cases that have been revealed will need to be investigated further in order to formulate suitable recommendations.
Abstract
Background and Purpose Neuromyelitis optica spectrum disorder (NMOSD) is a rare demyelinating disease of the central nervous system (CNS). We investigated the medical behaviors of experts in Korea when they are diagnosing and treating NMOSD. Methods An anonymous questionnaire on the diagnosis and treatment of NMOSD was distributed to experts in CNS demyelinating diseases. Results Most respondents used the 2015 diagnostic criteria for NMOSD and applied a cerebrospinal fluid examination, magnetic resonance imaging (MRI) of the brain and spine, and anti-aquaporin-4 antibody testing to all suspected cases of NMOSD. All respondents prescribed steroid pulse therapy as an first-line therapy in the acute phase of NMOSD, and 67% prescribed azathioprine for maintenance therapy in NMOSD. However, details regarding monitoring, the tapering period of oral steroids, second-line therapy use in refractory cases, management during pregnancy, and schedule of follow-up MRI differed according to the circumstances of individual patients. We analyzed the differences in response rates between two groups of respondents according to the annual number of NMOSD patients that they treated. The group that had been treating ≥10 NMOSD patients annually preferred rituximab more often as the second-line therapy (p=0.011) and had more experience with rituximab treatment (p=0.015) compared with the group that had been treating <10 NMOSD patients. Conclusions This study has revealed that NMOSD experts in Korea principally follow the available treatment guidelines. However, the differences in specific clinical practices applied to uncertain cases that have been revealed will need to be investigated further in order to formulate suitable recommendations.
참고문헌 (30)
- Kim SH, "Central nervous system neuroinflammatory disorders in Asian", Pacific regions, 2016, pp.29, 372~380
- Wingerchuk DM, "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders", Neurology, 85, pp.177~189 (2015)
- Duchow A, "Emerging drugs for the treatment of neuromyelitis optica", Expert Opin Emerg Drugs, 25, pp.285~297 (2020)
- Sahraian MA, "Diagnosis and management of neuromyelitis optica spectrum disorder(NMOSD)in Iran : a consensus guideline and recommendations", Mult Scler Relat Disord, 18, pp.144~151 (2017)
- Franciotta D, "Diagnostics of the neuromyelitis optica spectrum disorders(NMOSD)", Neurol Sci, 38, pp.231~236 (2017)
- Palace J, "A practical guide to the treatment of neuromyelitis optica", Pract Neurol, 12, pp.209~214 (2012)
- K. M Society, "Clinical practice guideline for diagnosis of neuromyelitis optica by Korean MS society", MS society, ~ (2012)
- Kim JE, "Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea", Mult Scler, 26, pp.1837~1844 (2020)
- HYELIM LEE, "Prevalence and Incidence of Neuromyelitis Optica Spectrum Disorder in Korea: Population Based Study", Journal of Korean Medical Science, 35(17), pp.1~9 (2020), 대한의학회[DOI]
- Lee HL, "Establishment and management of neuromyelitis optica(NMO)and NMO spectrum disorders(NMOSD)nationwide multicenter registry in Korea", Mult Scler J, 24, pp.411~ (2018)
- Wingerchuk DM, "Revised diagnostic criteria for neuromyelitis optica", Neurology, 66, pp.1485~1489 (2006)
- D’Souza M, "Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders : results of an international survey", Mult Scler Relat Disord, 41, pp.102027~ (2020)
- Chen H, "Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder", Eur J Neurol, 24, pp.219~226 (2017)
- Xu Y, "Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder : a prospective cohort study", J Neurol Sci, 370, pp.224~228 (2016)
- Rovira À, "Evidence-based guidelines : MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process", Nat Rev Neurol, 11, pp.471~482 (2015)
- Miller DH, "Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis", Ann Neurol, 39, pp.6~16 (1996)
- Lee MY, "Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder", Neurology, 95, pp.e3124~e3128 (2020)
- Shosha E, "Disease-modifying therapies should be stopped in NMOSD patients in remission-Yes", Mult Scler, 25, pp.1217~1218 (2019)
- Akaishi T, "Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence", Neurol Neuroimmunol Neuroinflamm, 7, pp.e640~ (2020)
- Kim SH, "A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder", JAMA Neurol, 70, pp.1110~1117 (2013)
- Damato V, "Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders : a systematic review and meta-analysis", JAMA Neurol, 73, pp.1342~1348 (2016)
- Ip VH, "Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders", J Neurol Sci, 324, pp.38~39 (2013)
- Kim SC, "Editorial : safety of immunosuppressive drugs in pregnant women with systemic inflammatory diseases", Arthritis Rheumatol, 66, pp.246~249 (2014)
- McGee DC, "Steroid use during pregnancy", J Perinat Neonatal Nurs, 16, pp.26~39 (2002)
- Das G, "Rituximab before and during pregnancy : a systematic review, and a case series in MS and NMOSD", Neurol Neuroimmunol Neuroinflamm, 5, pp.e453~ (2018)
- Kim SH, "Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder", Eur J Neurol, 27, pp.1546~1555 (2020)
- Selmaj K, "Novel emerging treatments for NMOSD", Neurol Neurochir Pol, 53, pp.317~326 (2019)
- Longoni G, "Rituximab as a first-line preventive treatment in pediatric NMOSDs : preliminary results in 5children", Neurol Neuroimmunol Neuroinflamm, 1, pp.e46~ (2014)
- Zéphir H, "Rituximab as first-line therapy in neuromyelitis optica : efficiency and tolerability", J Neurol, 262, pp.2329~2335 (2015)
- Nikoo Z, "Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder : a randomized clinical trial", J Neurol, 264, pp.2003~2009 (2017)